Autolus Therapeutics (NASDAQ:AUTL) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a report published on Friday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

AUTL has been the subject of several other research reports. Truist Financial raised shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday. Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Finally, HC Wainwright started coverage on Autolus Therapeutics in a research report on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Autolus Therapeutics Stock Performance

NASDAQ AUTL opened at $1.21 on Friday. The business has a fifty day moving average price of $1.49 and a 200 day moving average price of $1.52. The company has a market cap of $322.03 million, a P/E ratio of -1.46 and a beta of 1.95. Autolus Therapeutics has a one year low of $1.11 and a one year high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Friday, March 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.07). The business had revenue of $24.29 million for the quarter, compared to analyst estimates of $23.92 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. As a group, sell-side analysts predict that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AUTL. Mak Capital One LLC increased its holdings in Autolus Therapeutics by 53.5% in the 3rd quarter. Mak Capital One LLC now owns 26,017,616 shares of the company’s stock valued at $42,409,000 after purchasing an additional 9,062,518 shares during the last quarter. Armistice Capital LLC lifted its stake in Autolus Therapeutics by 9.1% during the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock worth $27,360,000 after purchasing an additional 1,000,000 shares in the last quarter. TFG Asset Management GP Ltd lifted its stake in Autolus Therapeutics by 10.5% during the second quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock worth $21,660,000 after purchasing an additional 900,000 shares in the last quarter. Cetera Investment Advisers boosted its position in shares of Autolus Therapeutics by 17.6% during the second quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock worth $1,407,000 after buying an additional 92,300 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Autolus Therapeutics in the second quarter valued at $1,288,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Autolus Therapeutics

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Company reiterated 2026 guidance: management expects AUCATZYL® net product revenue of $120–$135M and a shift to positive gross margin in 2026 — a clear path to improving unit economics and cash-generation visibility. Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
• Positive Sentiment: Commercial traction: AUCATZYL reported ~$23.3M net product revenue in Q4 and $74.3M for FY2025; UK launch underway after positive NICE evaluation and real‑world data show favorable activity/safety — supports revenue ramp thesis. Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst upgrades/price target upside: Needham reaffirmed a Buy with a $10 PT (large theoretical upside from current levels) and Truist upgraded to Strong-Buy — these notes can attract speculative buying ahead of clinical readouts. Benzinga
• Neutral Sentiment: Pipeline catalyst timeline: pivotal Phase 2 trials enrolling in lupus nephritis and pediatric ALL; initial BOBCAT Phase 1 data in progressive MS expected late 2026 — potential upside but not immediate. Press Release
• Neutral Sentiment: Company hosted an earnings call and published the transcript/slides — useful for detail on margin assumptions and cash runway into Q4 2027. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings miss and weak profitability metrics: Q4 EPS of ($0.34) missed consensus ($0.27); company still deeply unprofitable with a large negative net margin and negative ROE — these metrics pressure sentiment in the near term. Press Release / Slide Deck
• Negative Sentiment: Analyst caution: Some outlets (and at least one analyst note) highlight a challenging risk/reward despite strong B-ALL data, citing reliance on upcoming autoimmune and pediatric data to re‑rate the stock. Seeking Alpha Hold-perspective

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.